To include your compound in the COVID-19 Resource Center, submit it here.

Melacine: Phase III data; marketed in Canada

Additional data from CRXA's 689-patient Phase III trial of Melacine showed that 38 percent of patients in the

Read the full 188 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE